Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.

MLA

Grossberg, George T., et al. “Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.” The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry, vol. 28, no. 4, Apr. 2020, pp. 383–400. EBSCOhost, https://doi.org/10.1016/j.jagp.2019.09.009.

APA

Grossberg, G. T., Kohegyi, E., Mergel, V., Josiassen, M. K., Meulien, D., Hobart, M., Slomkowski, M., Baker, R. A., McQuade, R. D., & Cummings, J. L. (2020). Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry, 28(4), 383–400. https://doi.org/10.1016/j.jagp.2019.09.009

Chicago

Grossberg, George T, Eva Kohegyi, Victor Mergel, Mette Krog Josiassen, Didier Meulien, Mary Hobart, Mary Slomkowski, Ross A Baker, Robert D McQuade, and Jeffrey L Cummings. 2020. “Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.” The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry 28 (4): 383–400. doi:10.1016/j.jagp.2019.09.009.